Trial site
Beijing Luhe Hospital, Capital Medical University
Beijing, Beijing Municipality 101149, ChinaNot linked to an institution yet
- 14running trials
- 12closed trials
The trials here
What the 26 trials at this site are about, from their registry records.
- Phase
- Phase 311 trials
- Phase 25 trials
- Phase 1/22 trials
- Phase 41 trial
- Status
- Completed10 trials
- Recruiting6 trials
- Active, not recruiting4 trials
- Not yet recruiting4 trials
- Terminated2 trials
- Lead sponsor
- Janssen Research & Development, LLC3 trials
- BeiGene2 trials
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.2 trials
- Akeso1 trial
- Beijing Chao Yang Hospital1 trial
- and 17 more
Running trials
Recruiting
A Phase Ib/IIa Study of INT-210 Capsules in Participants With Active Ulcerative Colitis
NCT07692165· Phase 1/2· Innatus Therapeutics (Shanghai) Co., Ltd.· Source
Contact: Wang
Recruiting
Single vs. Dual Antiplatelet Therapy in Patients Undergoing Percutaneous Intervention With DCB-only Strategy (KONG-FREEDOM-I)
NCT07587099· Gan Lijun· Source
Contact: Guangyao Zhai
Recruiting
A Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer
NCT07225946· Phase 3· Janssen Research & Development, LLC· Source
Not yet recruiting
Prognostic Model for MASLD Related Cirrhosis
NCT07082751· Beijing Friendship Hospital· Source
Contact: Baohong Xu
Recruiting
A Study of AK112 as Consolidation Treatment for Patients With Limited Stage Small-cell Lung Cancer Who Have Not Progressed Following Concurrent Chemoradiation Therapy
NCT07010263· Phase 3· Akeso· Source
Contact: Dong Yan, M.D.
Recruiting
Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors
NCT06993844· Phase 1/2· Ensem Therapeutics· Source
Contact: Dong Yan
Recruiting
Comparative Effectiveness of Intervention in Multi-level Hospitals for Acute Traumatic Brain Injury(Metric-TBI)
NCT06429774· Beijing Tiantan Hospital· Source
Contact: Weiming Liu, M.D.
Recruiting
Efficacy and Safety of LT3001 on Treating the Acute Ischemic Stroke
NCT05686642· Phase 2· Shanghai Pharmaceuticals Holding Co., Ltd· Source
Contact: Yanling Wang
Active, not recruiting
A Study of TAR-200 in Combination With Cetrelimab or TAR-200 Alone Versus Intravesical Bacillus Calmette-Guérin (BCG) in Participants With BCG-naïve High-risk Non-muscle Invasive Bladder Cancer (HR-NMIBC)
NCT05714202· Phase 3· Janssen Research & Development, LLC· Source
Active, not recruiting
A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers
NCT05152147· Phase 3· Jazz Pharmaceuticals· Source
Not yet recruiting
Optimized Antiplatelet Therapy in Patients With CHD After Implantation of NeoVas™ BRS System
NCT04995159· Lepu Medical Technology (Beijing) Co., Ltd.· Source
Contact: Jincheng Guo
Active, not recruiting
A Clinical Study to Evaluate the Long-Term Safety Sodium Oligomannate Capsules (GV-971)
NCT05058040· Phase 4· Green Valley (Shanghai) Pharmaceuticals Co., Ltd.· Source
Active, not recruiting
A Phase III Clinical Trial of AK105 Injection Combined With Anlotinib Hydrochloride Capsules Versus Sorafenib in Subjects With Advanced Hepatocellular Carcinoma (HCC)
NCT04344158· Phase 3· Chia Tai Tianqing Pharmaceutical Group Co., Ltd.· Source
Recruiting
Development and Application of a Thrombosis Risk Prediction Model in Lung Cancer Patients Treated With Immune Checkpoint Inhibitors
NCT06950697· Beijing Chao Yang Hospital· Source
Contact: Yuan Yuan
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
Closed trials
Completed
Feasibility and Preliminary Efficacy of a Theory-driven BALANCE Dietary Program Among Patients With Type 2 Diabetes
NCT07472855· Capital Medical University· Source
Completed
Prospective, Multicenter, Self-controlled Clinical Trial to Validate Optical Ultrasonic Flow Ratio (OUFR)
NCT06726252· Harbin Medical University· Source
Completed
Efficacy and Safety of Berberine Ursodeoxycholate (HTD1801) in Patients With Type 2 Diabetes Inadequately Controlled With Metformin
NCT06353347· Phase 3· Shenzhen HighTide Biopharmaceutical Ltd.· Source
Completed
A Clinical Study to Evaluate the Efficacy and Safety of Subcutaneous JS005 Injection in the Treatment of Adults With Moderate to Severe Chronic Plaque Psoriasis
NCT05975268· Phase 3· Shanghai Junshi Bioscience Co., Ltd.· Source
Completed
A Phase 2b, Randomized, Double-blind Study of Redasemtide (S-005151) in Adult Participants With Acute Ischemic Stroke
NCT05953480· Phase 2· Shionogi· Source
Terminated
Study To Investigate the Efficacy and Safety of Sitravatinib in Combination With Tislelizumab in Participants With Esophageal Squamous Cell Carcinoma
NCT05461794· Phase 2· BeiGene· Source
Terminated
Rituximab Combined With Cyclosporine Versus Rituximab Alone in the Treatment of iMN
NCT04743739· Phase 3· Peking Union Medical College Hospital· Source
Completed
EMPACT-MI: A Study to Test Whether Empagliflozin Can Lower the Risk of Heart Failure and Death in People Who Had a Heart Attack (Myocardial Infarction)
NCT04509674· Phase 3· Boehringer Ingelheim· Source
Completed
A Study of Atezolizumab Plus Tiragolumab in Combination With Paclitaxel and Cisplatin Compared With Paclitaxel and Cisplatin as First-Line Treatment in Participants With Unresectable Locally Advanced, Unresectable Recurrent, or Metastatic Esophageal Carcinoma
NCT04540211· Phase 3· Hoffmann-La Roche· Source
Completed
A Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule in Subjects With Advanced Endometrial Cancer
NCT04574284· Phase 2· Chia Tai Tianqing Pharmaceutical Group Co., Ltd.· Source
Completed
A Study of Erdafitinib in Participants With Advanced Solid Tumors and Fibroblast Growth Factor Receptor (FGFR) Gene Alterations
NCT04083976· Phase 2· Janssen Research & Development, LLC· Source
Completed
Tislelizumab in Combination With Chemotherapy as First-Line Treatment in Adults With Inoperable, Locally Advanced or Metastatic Gastric, or Gastroesophageal Junction Carcinoma
NCT03777657· Phase 3· BeiGene· Source
Report an error